Russell E. Schuster III, serving as the Chief Commercial Officer for AdaptHealth Corp. (NASDAQ:AHCO), completed a transaction involving the sale of company equity on July 1, 2026. The total value of this disposition reached $117,711. The transaction consisted of the sale of 11,275 shares. The execution price for these shares was recorded at $10.44 per share. Following the completion of this sale, Mr. Schuster retains a direct holding of 125,263 shares of AdaptHealth common stock. The price at which the shares were sold represents a slight premium relative to the current stock price of $10.27. This current trading price sits below the Fair Value estimate provided by InvestingPro, which may suggest that the stock is undervalued at its present levels.
The sale was executed automatically pursuant to a Rule 10b5-1 trading plan. Mr. Schuster originally adopted this plan on March 2, 2026. This structured approach to trading is designed to facilitate transactions in compliance with securities regulations. The company recently reported its first quarter 2026 earnings, which revealed a miss on earnings per share (EPS). The reported EPS was -$0.12, which fell short of the forecasted $0.01. Despite the earnings miss, the company exceeded revenue expectations. Revenue achieved was $819.8 million, surpassing projections by 2.95 percent. This indicates that while profitability metrics faced headwinds, top-line growth remained robust.
AdaptHealth shareholders also approved all proposals at the company's recent annual meeting. A significant 88.67 percent of common shares were represented at the meeting, ensuring a quorum was met. This shareholder approval process underscores the governance mechanisms in place at the corporation. In terms of analyst sentiment, Truist Securities has maintained its Buy rating for AdaptHealth. The firm cited solid core trends and progress on a capitated contract as key factors supporting its outlook. The price target set by Truist Securities is $14.00. The firm also noted ongoing labor cost normalization around this contract, which may contribute to future margin improvement.
Despite the company's negative earnings of -$0.59 per share over the last twelve months, InvestingPro Tips indicate that analysts predict AdaptHealth will be profitable this year. Earnings are forecasted at $0.94 per share. This divergence between trailing twelve-month losses and forward-looking profitability suggests a potential inflection point for the company. The strategic focus and operational adjustments in a challenging market environment are reflected in these developments. Investors may monitor the capitated contract progress and labor cost trends as key indicators of the company's trajectory.